SEATTLE--(BUSINESS WIRE)--Curi Bio, a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of the Mantarray™ platform for human-relevant 3D ...
BOSTON and SEATTLE, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with ...
SEATTLE & BOSTON--(BUSINESS WIRE)--Curi Bio, the industry leader in delivering human functional data to the drug discovery community, and Novoheart, maker of the industry’s most sophisticated and ...
Medera announced that its wholly owned preclinical subsidiary for disease modelling and drug discovery, Novoheart, has entered into a partnership with Curi Bio. This strategic collaboration integrates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results